

Corporate Fact Sheet



Founded: 2004

Listed on SIX Swiss Exchange: 2014

Trading Symbol: MOLN

Number of employees: 120

Headquarters:

Molecular Partners AG

Wagistrasse 14

8952 Zürich-Schlieren

Switzerland

Phone: +41 44 755 77 00

Fax: +41 44 755 77 07

www.molecularpartners.com

Vision: A fully integrated Biotech in Oncology



Executive Management:

Patrick Amstutz, PhD

Founder and Chief Executive Officer

Michael Stumpp, PhD

Founder and Chief Scientific Officer

Andreas Emmenegger

Chief Financial Officer

Andreas Harstrick, MD

Chief Medical Officer

Contacts US

Media:

Alex Van Rees

973-442-1555 x 111

alex.vanrees@smithsolve.com

Investors:

Susan A. Noonan

212-966-3650

susan@sanoonan.com


ABOUT US

- Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies.
- With a management team that includes many of the company's founding scientists, Molecular Partners continues to attract talented individuals who share a passion for developing breakthrough medicines for serious diseases.
- Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology.
- The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.


DARPin®: MAKING THE DARPin® DIFFERENCE A REALITY FOR PATIENTS

- DARPin® therapeutics are a new class of protein therapeutics that open an extra dimension of multi-specificity and multi-functionality.
- DARPin® candidates are potent, specific, safe and very versatile. They can engage more than five targets at once, offering potential benefits over those provided by conventional monoclonal antibodies or other currently available protein therapeutics.
- The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields. With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapies have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

- Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology.
- The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development.
- The most advanced systemic DARPin® molecule, MP0250, is in a clinical POC study in multiple myeloma. In addition, Molecular Partners will evaluate MP0250 for the treatment of solid tumors in a phase 1b/2 trial in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
- MP0274, the company's second-most advanced DARPin® drug candidate in oncology, has entered into phase 1 clinical development. With its broad anti-HER activity, MP0274 inhibits HER1-, HER2- and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis.
- Molecular Partners has developed a tumor restricted boosting-concept for T-cells and beyond to avoid systemic side effects and reach higher efficacy at the tumor. The principle works for many tumor targets and multiple agonists or other very active mechanisms (like T-cell engagers). The local, tumor-restricted activation mechanism unlocks a matrix of potential combinations ("our toolbox"), of which MP0310 is the first development candidate with further candidates already identified and on the way.
- DARPin® is a registered trademark owned by Molecular Partners AG.




PIPELINE




INVESTMENT CASE

- Successful transition from DARPin® platform stage into clinical product company
- Oncology stepping out of Ophthalmology “shadow”
- Key news flow and value inflection points in 2018 for both, abicipar (phase 3 data) as well as for three clinical trials in oncology (phase 1 and phase 2)
- DARPin® engine: An unlimited source of future candidates
- Pre-clinical candidate MP0310 in immune-oncology: First tangible result from DARPin® toolbox to substantiate company’s “landmark claim”
- Financed beyond 2019, capturing key value inflection points
- Strategic ambition: Become a fully integrated and globally active biotech



SHARE INFORMATION AND FINANCIALS



- Pre-IPO investors (5 VC's)
- Management, Board, Founders
- Others

Share information (per June 30, 2017):

- Listed on SIX Swiss Exchange (ticker symbol: MOLN)
- Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech
- 20,794,606 shares outstanding
- CHF 610 million market cap., Formal free float (SIX definition): 74%

Financials:

- Strong financial position with CHF 152 million in cash (Sep 30, 2017)
- Net cash used in operating activities of CHF 28.5 million (Q1-Q3 2017)